https://mb.cision.com/Public/18595/logo/86a99b25f755738d_org.jpg
** UCB's General Meeting of Shareholders 2021
------------------------------------------------------------
=C2=B7 For financial year 2020: Gross dividend of =E2=82=AC 1.27 per share =
(+ 2 %), payable 4 May 2021
=C2=B7 All agenda items put to vote approved
=C2=B7 The message of Jean-Christophe Tellier, CEO of UCB is available on U=
CB=E2=80=99s global corporate website
Brussels (Belgium), 29 April 2020 =E2=80=93 18:00 (CEST) =E2=80=93 regulate=
d information - Today, UCB held its Annual General Meeting of Shareholders =
(AGM). In view of the measures adopted by public authorities to fight again=
st the Covid-19 pandemic and in accordance with article 7:137 of the Belgia=
n code of companies and associations, this meeting was organised virtually.=
=C2=A0At the AGM 148 614 833=C2=A0shares (78,73% of shares entitled to vot=
e) were present or=C2=A0represented.=C2=A0The message of Mr. Jean-Christoph=
e Tellier, Chief Executive Officer of UCB, published at the occasion of thi=
s general meeting, is available on the UCB website (https://www.ucb.com/inv=
estors/UCB-shareholders/Shareholders-meeting-2021) .
During his speech, Mr. Tellier commented: =E2=80=9CThanks to our resilient =
teams, 2020 was another excellent year for UCB. We delivered strong results=
, proving once again that we can be confident that our current growth strat=
egy supports our ability to care, grow and deliver=E2=80=9D.=C2=A0
Jean-Christophe Tellier also highlighted in his message the company=E2=80=
=99s performance to date in 2021: =E2=80=9CWe see the continuation of the g=
ood performance in 2020 =E2=80=93 in-line with our expectations and in-line=
with our guidance for 2021.=E2=80=9D On the topic of the pandemic, Mr. Tel=
lier added: =E2=80=9CWe will continue to closely follow the evolving COVID-=
19 pandemic and its implications diligently to assess potential near- and m=
id-term challenges. As of today, we confirm all timelines for UCB=E2=80=99s=
clinical development programs as communicated during our FY 2020 report en=
d of February. UCB will continue to monitor the impact of COVID-19 on all o=
ngoing clinical trials and will implement changes as necessary.=C2=A0
Looking at UCB=E2=80=99s FcRn antibody rozanolixizumab, Jean-Christophe Tel=
lier pointed out: =E2=80=9Cwe are going to investigate an additional patien=
t population of people living with Autoimmune encephalitis (AIE) =E2=80=93 =
a rare and serious medical condition, in which the immune system attacks th=
e brain - leading to epileptic seizures, movement disorders as well as onse=
t of cognitive decline in some patients. There is no therapy approved for A=
IE. UCB=E2=80=99s clinical development program with rozanolixizumab in AIE =
will start with a phase 2 study in this patient population during the third=
quarter this year. First results are expected in Q4 2023.=E2=80=9D
The AGM approved for the fiscal year 2020 the payment of a gross dividend o=
f =E2=82=AC 1.27 per share (net dividend of =E2=82=AC 0.889 per share) comp=
ared to =E2=82=AC 1.24 per share for 2019 (net =E2=82=AC 0.868). The ex-div=
idend date is 30 April 2021, the dividend (coupon no. 24) will be payable a=
s of 4 May 2021.
During the AGM, several changes to the Board composition were approved. The=
AGM appointed Mr. Stefan Oschmann as Independent Director. He will become =
Chair of the Board in replacement of Mrs. Evelyn du Monceau who has reached=
the statutory age limit after serving on the Board for more than 35 years.=
Mrs. Fiona du Monceau was also appointed as Director. She will become Vice=
Chair of the Board in replacement of Mr. Pierre Gurdjian who will stay on =
the Board as Independent Director for the remainder of his mandate. Fiona d=
u Monceau is a representative of the Reference Shareholder and does not qua=
lify as independent Director in accordance with the criteria of the 2020 Co=
de.
Upon reaching the end of his mandate, Mr. Roch Doliveux did not wish to app=
ly for a new term for personal reasons and as such has left the Board and U=
CB. Mr. Jonathan Peacock was appointed as Independent Director and will bec=
ome the Chair of the Audit Committee in replacement of Mr. Albrecht De Grae=
ve. Mr. De Graeve=E2=80=99s mandate was renewed for a term of 4 years and h=
e will continue to qualify as Independent Director until the General Meetin=
g of 2022.=C2=A0
The mandate of Mrs. Viviane Monges as independent member of the Board was r=
enewed for a term of 4 years. She will continue to be a member of the Audit=
Committee. Professor Susan Gasser was appointed as a new member of UCB=E2=
=80=99s Board of Directors. Professor Gasser replaces Professor Alice Dautr=
y who has reached the statutory age limit and will continue to be a member =
of the Scientific Committee of the Board. Her co-optation in the Board for =
the period starting on January 1, 2021 was also confirmed. =C2=A0
Commenting on the Board changes, Jean-Christophe Tellier gave special thank=
s personally and on behalf of UCB to those leaving after many years of grea=
t service to the company: =E2=80=9CI=E2=80=99d like to show my appreciation=
and gratitude to our Chair of the Board, Evelyn du Monceau who retired at =
the end of the meeting. Her expertise and guidance have been invaluable. Ev=
elyn has always demonstrated an unwavering commitment to advancing better c=
are and treatment solutions for patients with unmet needs. Jean-Christophe =
also wished to thank past UCB CEO and Board member Roch Doliveux who is als=
o leaving the Board: =E2=80=9CRoch steered UCB for many years and was instr=
umental into helping the company transform into a successful biopharma play=
er. We worked together for many years and I=E2=80=99ve always welcomed his =
guidance and support.=E2=80=9D=C2=A0
For the curriculum vitae of the Board members, please visit the UCB website=
: https://www.ucb.com/investors/UCB-governance.=C2=A0
All other agenda items put to vote at the AGM were approved by the sharehol=
ders. More information including details of the votes will be available soo=
n on UCB's website (https://www.ucb.com/investors/UCB-shareholders/Sharehol=
ders-meeting-2021) .
The Integrated Annual Report 2020 of UCB can be downloaded on UCB's website=
at https://www.ucb.com/investors/Download-center or is available on the on=
line portal at https://reports.ucb.com/annual-report-2020/home.
=C2=A0
The financial results for the first half year 2021 will be published on 29 =
July 2021.=C2=A0
Next year's General Meeting will be held on 28 April 2022.
For further information
Investor Relations
Antje Witte =C2=A0 =C2=A0 =C2=A0 =C2=A0 =C2=A0
Investor Relations, UCB
T +32.2.559.94.14 antje.witte@ucb.com
Corporate Communications
Laurent Schots=C2=A0
Media Relations, UCB =C2=A0
T+32.2.559.92.64 =C2=A0Laurent.schots@ucb.com=C2=A0
=C2=A0=C2=A0
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With approximately 8 400 peopl=
e in nearly 40 countries, the company generated revenue of =E2=82=AC 5.3 bi=
llion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). Follow us =
on Twitter: @UCB_news
Forward looking statements UCB
This press release may contain forward-looking statements including, withou=
t limitation, statements containing the words =E2=80=9Cbelieves=E2=80=9D, =
=E2=80=9Canticipates=E2=80=9D, =E2=80=9Cexpects=E2=80=9D, =E2=80=9Cintends=
=E2=80=9D, =E2=80=9Cplans=E2=80=9D, =E2=80=9Cseeks=E2=80=9D, =E2=80=9Cestim=
ates=E2=80=9D, =E2=80=9Cmay=E2=80=9D, =E2=80=9Cwill=E2=80=9D, =E2=80=9Ccont=
inue=E2=80=9D and similar expressions. These forward-looking statements are=
based on current plans, estimates and beliefs of management. All statement=
s, other than statements of historical facts, are statements that could be =
deemed forward-looking statements, including estimates of revenues, operati=
ng margins, capital expenditures, cash, other financial information, expect=
ed legal, arbitration, political, regulatory or clinical results or practic=
es and other such estimates and results. By their nature, such forward-look=
ing statements are not guarantees of future performance and are subject to =
known and unknown risks, uncertainties and assumptions which might cause th=
e actual results, financial condition, performance or achievements of UCB, =
or industry results, to differ materially from those that may be expressed =
or implied by such forward-looking statements contained in this press relea=
se. Important factors that could result in such differences include: the gl=
obal spread and impact of COVID-19, changes in general economic, business a=
nd competitive conditions, the inability to obtain necessary regulatory app=
rovals or to obtain them on acceptable terms or within expected timing, cos=
ts associated with research and development, changes in the prospects for p=
roducts in the pipeline or under development by UCB, effects of future judi=
cial decisions or governmental investigations, safety, quality, data integr=
ity or manufacturing issues; potential or actual data security and data pri=
vacy breaches, or disruptions of our information technology systems, produc=
t liability claims, challenges to patent protection for products or product=
candidates, competition from other products including biosimilars, changes=
in laws or regulations, exchange rate fluctuations, changes or uncertainti=
es in tax laws or the administration of such laws, and hiring and retention=
of its employees. There is no guarantee that new product candidates will b=
e discovered or identified in the pipeline, will progress to product approv=
al or that new indications for existing products will be developed and appr=
oved. Movement from concept to commercial product is uncertain; preclinical=
results do not guarantee safety and efficacy of product candidates in huma=
ns. So far, the complexity of the human body cannot be reproduced in comput=
er models, cell culture systems or animal models. The length of the timing =
to complete clinical trials and to get regulatory approval for product mark=
eting has varied in the past and UCB expects similar unpredictability going=
forward. Products or potential products which are the subject of partnersh=
ips, joint ventures or licensing collaborations may be subject to differenc=
es disputes between the partners or may prove to be not as safe, effective =
or commercially successful as UCB may have believed at the start of such pa=
rtnership. UCB=E2=80=99 efforts to acquire other products or companies and =
to integrate the operations of such acquired companies may not be as succes=
sful as UCB may have believed at the moment of acquisition. Also, UCB or ot=
hers could discover safety, side effects or manufacturing problems with its=
products and/or devices after they are marketed. The discovery of signific=
ant problems with a product similar to one of UCB=E2=80=99s products that i=
mplicate an entire class of products may have a material adverse effect on =
sales of the entire class of affected products. Moreover, sales may be impa=
cted by international and domestic trends toward managed care and health ca=
re cost containment, including pricing pressure, political and public scrut=
iny, customer and prescriber patterns or practices, and the reimbursement p=
olicies imposed by third-party payers as well as legislation affecting biop=
harmaceutical pricing and reimbursement activities and outcomes. Finally, a=
breakdown, cyberattack or information security breach could compromise the=
confidentiality, integrity and availability of UCB=E2=80=99s data and syst=
ems.=C2=A0
Given these uncertainties, you should not place undue reliance on any of su=
ch forward-looking statements. There can be no guarantee that the investiga=
tional or approved products potentially described in this press release wil=
l be submitted or approved for sale or for any additional indications or la=
belling in any market, or at any particular time, nor can there be any guar=
antee that such products will be or will continue to be commercially succes=
sful in the future.
UCB is providing this information, including forward-looking statements, on=
ly as of the date of this press release and it does not reflect any potenti=
al impact from the evolving COVID-19 pandemic, unless indicated otherwise. =
UCB is following the worldwide developments diligently to assess the financ=
ial significance of this pandemic to UCB. UCB expressly disclaims any duty =
to update any information contained in this press release, either to confir=
m the actual results or to report or reflect any change in its forward-look=
ing statements with regard thereto or any change in events, conditions or c=
ircumstances on which any such statement is based, unless such statement is=
required pursuant to a
GenericFile
20210421 - UCB AGM PR ENG (https://mb.cision.com/Public/18595/3337063/96f02=
bd20f0e17d7.pdf) GenericFile
20210421 - UCB AGM PR NL (https://mb.cision.com/Public/18595/3337063/b97b90=
855b6c3690.pdf) GenericFile
20210421 - UCB AGM PR FR (https://mb.cision.com/Public/18595/3337063/a957ba=
39dbc55b0b.pdf)
______________________
If you would rather not receive future communications from UCB SA, please g=
o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x68124x1x6868579x24000=
x6&Email=3Dregnews%40symexglobal.com.
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium
26/04/2024 20:00
25/04/2024 18:00
25/04/2024 07:01
23/04/2024 20:00
22/04/2024 07:01
19/04/2024 20:00
17/04/2024 07:01
12/04/2024 20:00
12/04/2024 18:01
12/04/2024 07:01